The impact of docosahexaenoic acid on alzheimer’s disease: Is there a role of the blood-brain barrier?

Current Clinical Pharmacology

Volumn 10, Issue 3, 2015, Pages 222-241

  Pan, Yijun ^a   Khalil, Hanan ^a   Nicolazzo, Joseph A ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Alzheimer s disease; Blood brain barrier; Docosahexaenoic acid; Fish oil; Omega 3 fatty acid; Polyunsaturated fatty acid

Indexed keywords

DOCOSAHEXAENOIC ACID; LIPID; OMEGA 3 FATTY ACID; FISH OIL;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TRANSPORT; FAT INTAKE; FATTY ACID BLOOD LEVEL; HUMAN; LIPID BRAIN LEVEL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; ANIMAL; BRAIN; DIET THERAPY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS, OMEGA-3; FISH OILS; HUMANS;

EID: 84940905373     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488471003150820151532     Document Type: Article

References (174)

1. Imbimbo BP, Lombard J, Pomara N. Pathophysiology of Alzheimer's disease. Neuroimaging. Clin N Am. 2005; 15(4): 727-53.
2. Thies W, Bleiler L, Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimer's Dement 2013; 9(2): 208-45.
3. DeKosky ST. Epidemiology and pathophysiology of Alzheimer's disease. Clin Cornerstone 2001; 3(4): 15-26.
4. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010; 362(4): 329-44.
5. Luchsinger JA, Noble JM, Scarmeas N. Diet and Alzheimer's disease. Curr Neurol Neurosci Rep 2007; 7(5): 366-72.
6. Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS. Fish consumption and cognitive decline with age in a large community study. Arch Neurol 2005; 62(12): 1849-53.
7. de Wilde MC, van der Beek EM, Kiliaan AJ, et al. Docosahexaenoic acid reduces amyloid-(1-42) secretion in human APP-transfected CHO-cells by mechanisms other than inflammation related to PGE2. J Alzheimers Dis 2010; 21(4): 1271-81.
8. Lim GP, Calon F, Morihara T, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci. 2005; 25(12): 3032-40.
9. Oksman M, Iivonen H, Hogyes E, et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 2006; 23(3): 563-72.
10. Hooijmans CR, Van der Zee CEEM, Dederen PJ, et al. DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis 2009; 33(3): 482-98.
11. Green KN, Martinez-Coria H, Khashwji H, et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 2007; 27(16): 4385-95.
12. Calon F. Omega-3 polyunsaturated fatty acids in Alzheimer's disease: key questions and partial answers. Curr Alzheimer Res 2011; 8(5): 470-8.
13. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81(2): 741-66.
14. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta amyloid in Alzheimer's disease. Science 2010; 330(6012): 1774.
15. Guo Q, Li H, Gaddam SSK, Justice NJ, Robertson CS, Zheng H. Amyloid precursor protein revisited: Neuron-specific expression and highly stable nature of soluble derivatives. J Biol Chem 2012; 287(4): 2437-45.
16. Banks WA, Robinson SM, Verma S, Morley JE. Efflux of human and mouse amyloid β proteins 1–40 and 1–42 from brain: impairmentin a mouse model of Alzheimer's disease. Neuroscience 2003; 121(2): 487-92.
17. Erickson MA, Banks WA. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab 2013; 33(10): 1500-13.
18. Yoshiyama Y, Lee VMY, Trojanowski JQ. Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry 2013; 84(7): 784-95.
19. Iqbal K, Alonso A, Gong C, et al. Molecular pathology of Alzheimer neurofibrillary degeneration. Acta Neurobiol Exp 1993; 53(1): 325-35.
20. Michaelis ML, Dobrowsky RT, Li G. Tau neurofibrillary pathology and microtubule stability. J Mol Neurosci 2002; 19(3): 289-93.
21. Terwel D, Dewachter I, Van Leuven F. Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease. Neuromolecular Med 2002; 2(2): 151-65.
22. Khlistunova I, Biernat J, Wang Y, et al. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 2006; 281(2): 1205-14.
23. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 2006; 281(51): 39413-23.
24. Santacruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005; 309(5733): 476-81.
25. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001; 293(5534): 1491-5.
26. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293(5534): 1487-91.
27. Oddo S, Caccamo A, Shepherd JD, et al. Triple transgenic model of Alzheimer's disease with plaques and tangles intracellular Abeta and synaptic dysfunction. Neuron 2003; 39(3): 409-21.
28. Gotz J, Xia D, Leinenga G, Chew YL, Nicholas H. What renders TAU toxic. Front Neurol 2013; 4: 72.
29. Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging 2003; 24(2): 321-31.
30. Farfara D, Lifshitz V, Frenkel D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med 2008; 12(3): 762-80.
31. Schultzberg M, Lindberg C, Aronsson AF, Hjorth E, Spulber SD, Oprica M. Inflammation in the nervous system physiological and pathophysiological aspects. Physiol Behav 2007; 92(1-2): 121-8.
32. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Diet and risk of dementia Does fat matter? The Rotterdam Study. Neurology 2002; 59(12): 1915-21.
33. Patel NS, Paris D, Mathura V, Quadros AN, Crawford FC, Mullan MJ. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation 2005; 2: 1-10.
34. Kitazawa M, Cheng D, Tsukamoto MR, et al. Blocking IL-1 signaling rescues cognition, attenuates tau pathology and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. J Immunol 2011; 187(12): 6539-49.
35. Vukic V, Callaghan D, Walker D, et al. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis 2009; 34(1): 95-106.
36. Apelt J, Schliebs R. Beta amyloid induced glial expression of both pro and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res 2001; 894(1): 21-30.
37. Perlmutter LS, Scott SA, Barron E, Chui HC. MHC class IIpositive microglia in human brain association with Alzheimer lesions. J Neurosci Res 1992; 33(4): 549-58.
38. Tooyama I, Kimura H, Akiyama H, McGeer PL. Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimer's disease. Brain Res 1990; 523(2): 273-80.
39. Uchihara T, Akiyama H, Kondo H, Ikeda K. Activated microglial cells are colocalized with perivascular deposits of amyloid-beta protein in Alzheimer's disease brain. Stroke 1997; 28(10): 1948-50.
40. Bourre JM. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing. J Nutr Health Aging 2004; 8(3): 163-74.
41. O'Brien JS. Stability of the myelin membrane. Science 1965; 147(3662): 1099-107.
42. Crawford MA, Sinclair AJ. Nutritional Influences in the Evolution of Mammalian Brain. Ciba Foundation Symposium 3-Lipids, Malnutrition & the Developing Brain, John Wiley and Sons Ltd 2008: 267-92.
43. Soderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991; 26(6): 421-5.
44. Corrigan FM, Horrobin DF, Skinner ER, Besson JA, Cooper MB. Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. Int J Biochem Cell Biol 1998; 30(2): 197-207.
45. Martin DD, Robbins ME, Spector AA, Wen BC, Hussey DH. The fatty acid composition of human gliomas differs from that found in nonmalignant brain tissue. Lipids 1996; 31(12): 1283-8.
46. Emken EA, Adlof RO, Gulley RM. Dietary linoleic acid influences desaturation and acylation of deuterium-labeled linoleic and linolenic acids in young adult males. Biochem Biophys Acta 1994; 1213(3): 277-88.
47. Fabelo N, Martin V, Santpere G, et al. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol Med 2011; 17(9-10): 1107-18.
48. Soderberg M, Edlund C, Alafuzoff I, Kristensson K, Dallner G. Lipid composition in different regions of the brain in Alzheimer's disease senile dementia of Alzheimer's type. J Neurochem 1992; 59(5): 1646-53.
49. Nakada T, Kwee IL, Ellis WG. Membrane fatty acid composition shows delta-6-desaturase abnormalities in Alzheimer's disease. Neuroreport 1990; 1(2): 153-5.
50. Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 1998; 23(1): 81-8.
51. Skinner ER, Watt C, Besson JA, Best PV. Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. Brain 1993; 116(3): 717-25.
52. Lukiw WJ, Cui JG, Marcheselli VL, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005; 115(10): 2774-83.
53. Kou J, Kovacs GG, Hoftberger R, et al. Peroxisomal alterations in Alzheimer's disease. Acta Neuropathol 2011; 122(3): 271-83.
54. Kim HY, Akbar M, Kim YS. Phosphatidyl serine-dependent neuroprotective signaling promoted by docosahexaenoic acid. Prostag Leukotr Ess 2010; 82(4-6): 165-72.
55. Guan Z, Wang Y, Cairns NJ, Lantos PL, Dallner G, Sindelar PJ. Decrease and structural modifications of phosphatidyl ethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol 1999; 58(7): 740-7.
56. Astarita G, Jung KM, Berchtold NC, et al. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One 2010;5(9):e12538.
57. Scott BL, Bazan NG. Membrane docosahexaenoate is supplied to the developing brain and retina by the liver. Proc Natl Acad Sci USA 1989; 86(8): 2903-7.
58. Fraser T, Tayler H, Love S. Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease. Neurochem Res 2010; 35(3): 503-13.
59. Cunnane SC, Schneider JA, Tangney C, et al. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2012; 29(3): 691-7.
60. Perez SE, Berg BM, Moore KA, et al. DHA diet reduces AD pathology in young APPswe/PS1 Delta E9 transgenic mice possible gender effects. J Neurosci Res 2010; 88(5): 1026-40.
61. Offe K, Dodson SE, Shoemaker JT, et al. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J Neurosci 2006; 26(5): 1596-603.
62. Andersen OM, Schmidt V, Spoelgen R, et al. Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry 2006; 45(8): 2618-28.
63. Spoelgen R, von Arnim CAF, Thomas AV, et al. Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. J Neurosci 2006; 26(2): 418-28.
64. Ma QL, Teter B, Ubeda OJ, et al. Omega-3 fatty acid docosahexaenoic acid increases SorLA/LR11, a sorting protein with reduced expression in sporadic Alzheimer's disease (AD): relevance to AD prevention. J Neurosci 2007; 27(52): 14299-307.
65. Zhao Y, Calon F, Julien C, et al. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase-and PPAR-mediated mechanisms in Alzheimer's disease models. PLoS One 2011; 6(1): e15816.
66. Belayev L, Khoutorova L, Atkins KD, Bazan NG. Robust docosahexaenoic acid-mediated neuroprotection in a rat model of transient, focal cerebral ischemia. Stroke 2009; 40(9): 3121-6.
67. Belayev L, Marcheselli VL, Khoutorova L, et al. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke 2005; 36(1): 118-23.
68. Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol. 2002; 156(3): 519-29.
69. Stein TD, Johnson JA. Genetic programming by the proteolytic fragments of the amyloid precursor protein somewhere between confusion and clarity. Rev Neurosci 2003; 14(4): 317-41.
70. Mozaffarian D, Wu JHY. (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr 2012; 142(3): 614S-25S.
71. Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutr 2012; 3(1): 1-7.
72. Calon F, Cole G. Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostag Leukotr Ess 2007; 77(5-6): 287-93.
73. Calder PC. Polyunsaturated fatty acids and inflammation. Prostag Leukotr Ess 2006; 75(3): 197-202.
74. Barberger Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues J-F, Renaud S. Fish, meat, and risk of dementia cohort study. Br Med J 2002; 325(7370): 932-3.
75. Barberger Gateau P, Raffaitin C, Letenneur L, et al. Dietary patterns and risk of dementia the Three-City cohort study. Neurology 2007; 69(20): 1921-30.
76. Laitinen MH, Ngandu T, Rovio S, et al. Fat intake at midlife and risk of dementia and Alzheimer's disease a population based study. Dement Geriatr Cogn Disord 2006; 22(1): 99-107.
77. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler M.M. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 1997; 42(5): 776-82.
78. Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003; 60(7): 940-6.
79. Huang TL, Zandi PP, Tucker KL, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 2005; 65(9): 1409-14.
80. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7(2): 180-4.
81. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res 2009; 50: S183-8.
82. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240(4852): 622-30.
83. Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harbor Perspectives in Medicine 2012; 2(10).
84. Devore EE, Grodstein F, van Rooij FJA, et al. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am J Clin Nutr 2009; 90(1): 170-6.
85. Hofman A, van Duijn CM, Franco OH, et al. The Rotterdam Study 2012 objectives and design update. Eur J Epidemiol 2011; 26(8): 657-86.
86. Cherubini A, Andres-Lacueva C, Martin A, et al. Low plasma N-3 fatty acids and dementia in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 2007; 62(10): 1120-6.
87. Corrigan FM, Van Rhijn AG, Ijomah G, et al. Tin and fatty acids in dementia. Prostag Leukotr Ess 1991; 43(4): 229-38.
88. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment.Lipids. 2000; 35(12): 1305-12.
89. Wang W, Shinto L, Connor WE, Quinn JF. Nutritional biomarkers in Alzheimer's disease: the association between carotenoids, n-3 fatty acids, and dementia severity. J Alzheimers Dis 2008; 13(1): 31-8.
90. Tully AM, Roche HM, Doyle R, et al. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a casecontrol study. Br J Nut 2003; 89(4): 483-9.
91. Schaefer EJ, Bongard V, Beiser AS, et al. Plasma phosphatidyl choline docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 2006; 63(11): 1545-50.
92. Whalley LJ, Deary IJ, Starr JM, et al. n-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: an observational follow-up study in late adulthood. Am J Clin Nutr 2008; 87(2): 449-54.
93. Kroger E, Verreault R, Carmichael PH, et al. Omega-3 fatty acids and risk of dementia the Canadian Study of Health and Aging. Am J Clin Nutr 2009; 90(1): 184-92.
94. Samieri C, Feart C, Letenneur L, et al. Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. Am J Clin Nutr 2008; 88(3): 714-21.
95. Ronnemaa E, Zethelius B, Vessby B, Lannfelt L, Byberg L, Kilander L. Serum fatty acid composition and the risk of Alzheimer's disease: a longitudinal population based study. Eur J Clin Nutr 2012; 66(8): 885-90.
96. Kyle DJ, Schaefer E, Patton G, Beiser A. Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Lipids 1999; 34: S245.
97. Dangour AD, Allen E, Elbourne D, et al. Effect of 2-y n-3 longchain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr 2010;91(6):1725-32.
98. Freund Levi Y, Vedin I, Cederholm T, et al. Transfer of omega-3 fatty acids across the blood–brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. J Int Med 2014; 275(4): 428-36.
99. Johnson EJ, McDonald K, Caldarella SM, Chung HY, Troen AM, Snodderly DM. Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutr Neurosci 2008; 11(2): 75-83.
100. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology 2008; 71(6): 430-8.
101. Yurko Mauro K, McCarthy D, Rom D, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimer's Dement 2010; 6(6): 456-64.
102. Andreeva VA, Kesse-Guyot E, Barberger-Gateau P, Fezeu L, Hercberg S, Galan P. Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids ancillary findings from the SU.FOL.OM3 randomized trial. Am J Clin Nutr 2011; 94(1): 278-86.
103. Geleijnse JM, Giltay EJ, Kromhout D. Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients. Alzheimer's Dement 2012; 8(4): 278-87.
104. Freund Levi Y, Hjorth E, Lindberg C, et al. Effects of omega-3 fatty Acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer’s disease the OmegADstudy. Dement Geriatr CognDisord 2009; 27(5): 481-90.
105. Freund Levi Y, Eriksdotter Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63(10): 1402-8.
106. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease a randomized trial. JAMA 2010; 304(17): 1903-11.
107. Mazereeuw G, Lanctot KL, Chau SA, Swardfager W, Herrmann N. Effects of omega-3 fatty acids on cognitive performance a metaanalysis. Neurobiol Aging 2012; 33(7): 1482.
108. Bowen RA, Clandinin MT. High dietary 18:3n-3 increases the 18:3n-3 but not the 22:6n-3 content in the whole body, brain, skin, epididymal fat pads, and muscles of suckling rat pups. Lipids 2000; 35(4): 389-94.
109. Green P, Yavin E. Elongation, desaturation, and esterification of essential fatty acids by fetal rat brain in vivo. J Lipid Res 1993; 34(12): 2099-107.
110. Su HM, Huang MC, Saad NM, Nathanielsz PW, Brenna JT. Fetal baboons convert 18:3n-3 to 22:6n-3 in vivo. A stable isotope tracer study. J Lipid Res 2001; 42(4): 581-6.
111. Shikano M, Masuzawa Y, Yazawa K, Takayama K, Kudo I, Inoue K. Complete discrimination of docosahexaenoate from arachidonate by 85 kDa cytosolic phospholipase A2 during the hydrolysis of diacyl-and alkenyl acylglycerophosphoethanolamine. Biochem Biophys Acta 1994; 1212(2): 211-6.
112. Vandal M, Alata W, Tremblay C, et al. Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. J Neurochem 2014; 129(3): 516-26.
113. Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. ActaNeuropathol 2006; 112(4): 405-15.
114. Vogelgesang S, Cascorbi I, Schroeder E, et al. Deposition of Alzheimer's beta-amyloid is inversely correlated with Pglycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002; 12(7): 535-41.
115. Harik SI. Changes in the glucose transporter of brain capillaries. Can J Physiol Pharmacol 1992; 70: S113-7.
116. Kalaria RN, Harik SI. Abnormalities of the glucose transporter at the blood-brain barrier and in brain in Alzheimer's disease. Prog Clin Biol Res 1989; 317: 415-21.
117. Johnson JK, Head E, Kim R, Starr A, Cotman CW. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 1999; 56(10): 1233-9.
118. Ross BM, Moszczynska A, Erlich J, Kish SJ. Phospholipid metabolizing enzymes in Alzheimer's disease increased lysophospholipidacyl transferase activity and decreased phospholipase A2 activity. J Neurochem 1998; 70(2): 786-93.
119. Montine TJ, Beal MF, Cudkowicz ME, et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999; 52(3): 562-5.
120. Nourooz Zadeh J, Liu EH, Yhlen B, Anggard EE, Halliwell B. F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J Neurochem 1999; 72(2): 734-40.
121. Chen CT, Green JT, Orr SK, Bazinet RP. Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostag Leukotr Ess 2008; 79(3-5): 85-91.
122. Hamilton J, Brunaldi K, Bazinet R, Watkins P. Brain Fatty Acid Uptake. Neural Metabolism In Vivo Springer 2012; 793-817.
123. Hamilton JA. Transport of fatty acids across membranes by the diffusion mechanism. Prostag Leukotr Ess 1999; 60(5-6): 291-7.
124. Hamilton JA, Johnson RA, Corkey B, Kamp F. Fatty acid transport: the diffusion mechanism in model and biological membranes. J Mol Neurosci 2001; 16(2-3): 99-108.
125. Mitchell RW, Hatch GM. Fatty acid transport into the brain: of fatty acid fables and lipid tails. Prostag Leukotr Ess 2011; 85(5): 293-302.
126. Hawkins BT, Davis TP. The blood brain barrier neurovascular unit in health and disease. Pharmacol Rev 2005; 57(2): 173-85.
127. Khan E. An examination of the blood-brain barrier in health and disease. Br J Nursing 2005; 14(9): 509-13.
128. Abbott NJ, Ronnback L, Hansson E. Astrocyte endothelial interactions at the blood brain barrier. Nat Rev Neurosci 2006; 7(1): 41-53.
129. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood brain barrier. Neurobiol Dis 2010; 37(1): 13-25.
130. Bourre JM, Durand G, Pascal G, Youyou A. Brain cell and tissue recovery in rats made deficient in n-3 fatty acids by alteration of dietary fat. J Nutr 1989; 119(1): 15-22.
131. Nag S, Begley DJ. Blood-brain barrier, exchange of metabolites and gases. In Pathology and Genetics. Cerebrovascular Diseases. ISN Neuropath Press; 2005.
132. Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 2002; 200(6): 629-38.
133. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier an overview structure, regulation, and clinical implications. Neurobiol Dis 2004; 16(1): 1-13.
134. Dehouck M.P, Meresse S, Delorme P, Fruchart JC, Cecchelli R. An easier, reproducible, and mass production method to study the blood-brain barrier in vitro. J Neurochem 1990; 54(5): 1798-801.
135. Estrada C, Bready JV, Berliner JA, Pardridge WM, Cancilla PA. Astrocyte growth stimulation by a soluble factor produced by cerebral endothelial cells in vitro. J Neuropathol Exp Neurol 1s990; 49(6): 539-49.
136. Haseloff RF, Blasig IE, Bauer HC, Bauer H. In search of the astrocytic factors modulating blood brain barrier functions in brain capillary endothelial cells in vitro. Cell Mol Neurobiol 2005; 25(1): 25-39.
137. Hayashi Y, Nomura M, Yamagishi S, Harada S, Yamashita J, Yamamoto H. Induction of various blood brain barrier properties in non neural endothelial cells by close apposition to cocultured astrocytes. Glia 1997; 19(1): 13-26.
138. Mi H, Haeberle H, Barres BA. Induction of astrocyte differentiation by endothelial cells. J Neurosci 2001; 21(5): 1538-47.
139. Rubin LL, Hall DE, Porter S, et al. A cell culture model of the blood-brain barrier. J Cell Biol 1991; 115(6): 1725-35.
140. Fenstermacher J, Gross P, Sposito N, Acuff V, Pettersen S, Gruber K. Structural and functional variations in capillary systems within the brain. Ann N Y Acad Sci 1988; 529: 21-30.
141. Kniesel U, Wolburg H. Tight junctions of the blood-brain barrier. Cell Mol Neurobiol 2000; 20(1): 57-76.
142. Sedlakova R, Shivers RR, Del Maestro RF. Ultrastructure of the blood brain barrier in the rabbit. J Submicroscopic Cytol Pathol 1999; 31(1): 149-61.
143. Crone C, Olesen SP. Electrical resistance of brain microvascular endothelium. Brain Res 1982; 241(1): 49-55.
144. Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. Prog Drug Res 2003; 61: 39-78.
145. Scherrmann JM. Drug delivery to brain via the blood–brain barrier. Vascular Pharmacol 2002; 38(6): 349-54.
146. Nicolazzo JA, Charman SA, Charman WN. Methods to assess drug permeability across the blood brain barrier. J Pharm Pharmacol 2006; 58(3): 281-93.
147. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12(12): 723-38.
148. Rapoport SI, Chang MC, Spector AA. Delivery and turnover of plasma derived essential PUFAs in mammalian brain. J Lipid Res 2001; 42(5): 678-85.
149. Rapoport SI, Rao JS, Igarashi M. Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostag Leukotr Ess. 2007; 77(5-6): 251-61.
150. Edmond J. Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport. J Mol Neurosci 2001; 16(2-3): 181-93.
151. Polozova A, Gionfriddo E, Salem N. Effect of docosahexaenoic acid on tissue targeting and metabolism of plasma lipoproteins. Prostag Leukotr Ess 2006; 75(3): 183-90.
152. Rahman T, Taha AY, Song BJ, et al. The very low density lipoprotein receptor is not necessary for maintaining brain polyunsaturated fatty acid concentrations. Prostag Leukotr Ess 2010; 82(2-3): 141-5.
153. Richieri GV, Kleinfeld AM. Unbound free fatty acid levels in human serum. J Lipid Res 1995; 36(2): 229-40.
154. Goti D, Balazs Z, Panzenboeck U, et al. Effects of lipoprotein lipase on uptake and transcytosis of low density lipoprotein and LDL associated alpha tocopherol in a porcine in vitro blood brain barrier model. J Biol Chem 2002; 277(32): 28537-44.
155. Levin VA. Relationship of octanol water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 1980; 23(6): 682-4.
156. Kamp F, Guo W, Souto R, Pilch PF, Corkey BE, Hamilton JA. Rapid flip flop of oleic acid across the plasma membrane of adipocytes. J Biol Chem 2003; 278(10): 7988-95.
157. Ouellet M, Emond V, Chen CT, Julien C, Bourasset F, Oddo S, et al. Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood brain barrier An in situ cerebral perfusion study. Neurochem Int 2009; 55(7): 476-82.
158. Mehta DC, Short JL, Nicolazzo JA. Altered brain uptake of therapeutics in a triple transgenic mouse model of Alzheimer’s disease. Pharm Res 2013; 30(11): 2868-79.
159. Mitchell RW, On NH, Del Bigio MR, Miller DW, Hatch GM. Fatty acid transport protein expression in human brain and potential role in fatty acid transport across human brain microvessel endothelial cells. J Neurochem 2011; 117(4): 735-46.
160. Harmon CM, Abumrad NA. Binding of sulfosuccinimidyl fatty acids to adipocyte membrane proteins isolation and amino terminal sequence of an 88-kD protein implicated in transport of long-chain fatty acids. J Membrane Biol 1993; 133(1): 43-9.
161. Coburn CT, Knapp FF, Febbraio M, Beets AL, Silverstein RL, Abumrad NA. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J Biol Chem 2000; 275(42): 32523-9.
162. Febbraio M, Abumrad NA, Hajjar DP, et al. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 1999; 274(27): 19055-62.
163. Ibrahimi A, Bonen A, Blinn WD, et al. Muscle specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle reduces plasma triglycerides and fatty acids and increases plasma glucose and insulin. J Biol Chem 1999; 274(38): 26761-6.
164. Abumrad NA, Sfeir Z, Connelly MA, Coburn C. Lipid transporters membrane transport systems for cholesterol and fatty acids. Curr Opin Clin Nutr Metab Care. 2000; 3(4): 255-62.
165. Schaffer JE, Lodish HF. Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell 1994; 79(3): 427-36.
166. Coe NR, Smith AJ, Frohnert BI, Watkins PA, Bernlohr DA. The fatty acid transport protein (FATP1) is a very long chain acyl-CoA synthetase. J Biol Chem. 1999; 274(51): 36300-4.
167. Hall AM, Smith AJ, Bernlohr DA. Characterization of the Acyl-CoA synthetase activity of purified murine fatty acid transport protein 1. J Biol Chem 2003; 278(44): 43008-13.
168. Watkins PA. Very long chain acyl-CoA synthetases. J Biol Chem 2008; 283(4): 1773-7.
169. Watkins PA, Maiguel D, Jia Z, Pevsner J. Evidence for 26 distinct acyl-coenzyme A synthetase genes in the human genome. J Lipid Res 2007; 48(12): 2736-50.
170. Jia Z, Moulson CL, Pei Z, Miner JH, Watkins PA. Fatty acid transport protein 4 is the principal very long chain fatty acyl-CoA synthetase in skin fibroblasts. J Biol Chem 2007; 282(28): 20573-83.
171. Mitchell RW, Edmundson CL, Miller DW, Hatch GM. On the mechanism of oleate transport across human brain microvessel endothelial cells. J Neurochem 2009; 110(3): 1049-57.
172. Ouali F, Djouadi F, Merlet-Benichou C, Riveau B, Bastin J. Regulation of fatty acid transport protein and mitochondrial and peroxisomal beta-oxidation gene expression by fatty acids in developing rats. Pediatr Res 2000; 48(5): 691-6.
173. Stahl A, Evans JG, Pattel S, Hirsch D, Lodish HF. Insulin causes fatty acid transport protein translocation and enhanced fatty acid uptake in adipocytes. Dev Cell 2002; 2(4): 477-88.
174. Nguyen LN, Ma D, Shui G, et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature 2014; 509(7501): 503-6.